Is the Semaglutide Injection Safe for Weight Loss?

What side effects do most people actually experience?

The honest answer is: most people feel some degree of nausea, particularly in the first few weeks. That's the GLP-1 mechanism doing exactly what it's designed to do, slowing how quickly your stomach empties and reducing appetite signals. Nausea, loose stools, constipation, indigestion, belching and fatigue are the most frequently reported effects in clinical trials. Injection-site reactions, mild dizziness and headache show up too, though less often.

A misconception worth gently setting aside: many people assume that feeling sick means something is going wrong. In most cases it means the medicine is working, and the sensation settles within a few days to a couple of weeks as your body adapts. Starting at the lowest dose (0.25mg) is designed specifically to give your system time to adjust before any increase.

The semaglutide weight-loss injection has a well-characterised side-effect profile built from the STEP clinical programme, and the NHS patient information for semaglutide sets out these common effects clearly. Eating smaller meals, staying well hydrated, and avoiding very fatty food during the early weeks helps most people get through the adjustment period more comfortably.

When should you get medical help straight away?

Most side effects are mild and self-limiting. A small number are not, and knowing the difference matters more than any other piece of safety information on this page.

Get urgent medical attention if you develop severe, persistent stomach pain that spreads into your back, with or without vomiting. This can be a sign of acute pancreatitis, a serious but infrequent reaction. In January 2026 the MHRA issued a Drug Safety Update specifically highlighting this risk with GLP-1 medicines, the update doesn't mean pancreatitis is common, but it does mean you shouldn't wait to see whether the pain passes.

Other symptoms that need prompt attention: signs of an allergic reaction (swelling of the face or throat, difficulty breathing, a fast heartbeat), severe dehydration following prolonged vomiting or diarrhoea, and gallbladder pain (a sharp ache under the right ribs, sometimes after eating). You can read the full list of warning signs on our semaglutide safety overview, or call 111 if you're unsure whether your symptoms need attention now.

If you ever want to flag a reaction formally, the MHRA's Yellow Card scheme accepts reports directly from patients, not only from healthcare professionals.

Who is the injection suitable for, and are there people it isn't right for?

The licensed eligibility for Wegovy covers adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. But BMI is a starting point, not the whole picture.

There are groups for whom the injection is not recommended. Pregnancy, breastfeeding and trying to conceive all sit outside the licensed indication; the current guidance recommends women use effective contraception throughout treatment. Semaglutide is not licensed for under-18s. People with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, or a history of pancreatitis, need a thorough prescriber discussion before anything is considered.

At nume, every consultation is reviewed personally by a GPhC-registered Independent Prescriber, a real clinician reading your answers, not a decision algorithm. Part of that review is checking for contraindications that an online questionnaire can surface but only a trained prescriber can properly weigh.

How does the semaglutide injection's safety record compare with its effectiveness?

The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults over 68 weeks and reported an average body-weight reduction of around 15% at the 2.4mg maintenance dose, a meaningful result that has shaped how NICE and NHS England view the medicine. Safety monitoring across the STEP programme found the side-effect profile consistent and predominantly GI-related, with serious adverse events uncommon and not materially different from placebo rates for most outcomes.

That said, this is still a relatively new medicine class. Wegovy carries a Black Triangle designation in the UK, which means the MHRA requires manufacturers to submit ongoing safety data. That's standard for recently licensed medicines and reflects how the regulatory system updates itself, new safety signals, if they emerge, are acted on quickly, as the January 2026 pancreatitis update illustrates.

If you're weighing up this route and want to understand how the weight loss pen semaglutide works in practice, this guide walks through the titration process and lifestyle factors that matter alongside treatment. If you're also looking into where to access semaglutide weight loss injections near you, it's worth knowing that a fully supervised online prescribing service can offer the same clinical oversight as an in-person clinic. And if you'd like to understand how weight loss injections such as Ozempic compare with licensed alternatives, our weight-loss treatment overview covers what's currently available in the UK. Our prescribers discuss both suitability and side effects as part of every consultation, and if you'd like a practical walkthrough of how to use semaglutide for weight loss, including dosing steps and injection technique, that guide is a good place to start before you begin. Start your free consultation to begin that conversation.